NHS
Leeds
Clinical Commissioning Group

Schedule 6 Part B of the Amber Audit LES
Process for Amber Level 3 Drug Payment and Audit by GP Practices for 2022/23

Amber Drug Payment

Payment process has not changed. Prescribing data for Amber Level 3 Drugs is collected directly from the clinical systems by the CCG on a quarterly basis. No further data needs to be submitted by the practice except for depot antipsychotics:

- There is a 2 tier payment for depot antipsychotics: Depots administered every 2 weeks will be paid at £66 per annum; those given less frequently than (eg every 4 weeks) will be paid at £40 per annum. The MOT will automatically run searches for depot antipsychotics prescribed each quarter and will pay practices at the default rate of £40. If this is correct there is no need to take any further action, however, if you have patients getting 2 weekly injections and wish to claim the higher rate please return details using Appendix 1 below.

Amber Drug Monitoring

The Local Enhanced Service (LES) for Amber Drug Monitoring by GP Practices requires practices to audit prescribing to confirm that amber level 3 drug agreements are being followed.

- During 2022.23 the CCG will produce audit data of a sample of monitoring requirements using data pulled from the clinical systems.
- This data will be reported back to the practices to review. Each practice should have a nominated person(s) responsible for reviewing this data.
- As in previous years the target compliance rate for monitoring is set at 80%, however the CCG is aware that temporary guidance for prescribers on drug monitoring during covid has allowed monitoring intervals to be extended, where this is thought appropriate, and searches have been amended to reflect this. Amber monitoring requirements are expected to revert to normal from 1st April 2022.
- The CCG will use the number of practices achieving the 80% target for each drug to monitor improvement in compliance. Practices will not need to submit action plans.
- Practices should still review the data supplied and should investigate if their performance is poorer than 80% or the CCG average.

.

The Audit Schedule

Quarter	Drug	Test Monitored
Quarter One – April, May & June	Oral Antipsychotics 1st generation -Benperidol, Chlorpromazine, Flupentixol, Haloperidol, Pericyazine, Perphenazine, Pimozide, Promazine, Sulpiride, Trifluoperazine, Zuclopenthixol	HBA1C in last 12 months
	Oral Antipsychotics 2nd generation - Amisulpride, Aripiprazole (oral), Olanzapine, Quetiapine, Risperidone (oral)	HBA1C in last 12 months
	Depot Antipsychotics - Aripiprazole depot, Flupentixol decanoate depot, Fluphenazine decanoate depot, Haloperidol decanoate depot, Paliperidone depot, Risperidone long acting injection, Zuclopenthixol depot	FBC last 12 months
	Azathioprine	FBC in last 3 months
	Enoxaparin	FBC in last 12 months
	Lithium	Li level in last 6 months
	Methotrexate	FBC in last 3 months
	DOACs	FBC in last 12 months
	Metyrapone	BP in last 3 months
	Sacubitril valsartan	BP in last 6 months
	Tinzaparin	FBC in last 12 months
	Warfarin	INR in last 3 months
Quarter Two – July, August & September	Agomelatine	LFT in last 12 months
	Amiodarone	LFT in last 6 months
	Atomoxetine	BP in last 6 months
	Azathioprine	FBC in last 3m
	Ciclosporin	BP in last 3 months
	Demeclocycline	FBC in last 4 months
	Denosumab	Calcium in last 6 m
	Dexamfetamine	BP in last 6 months
	DOACs	FBC in last 12m
	Dronedarone	LFT in last 12m
	Guanfacine	BP in last 6m
	Hydroxycarbamide	U&E in last 3m
	Leflunomide	U&E in last 3m
	Levamisole	U&E in last 3m
	Lisdexamphetamine	BP in last 6m
	Lithium	Lithium levels in last 6m
	Mepacrine	FBC in last 6m
	Mercaptopurine	LFT in last 3m
	Mesalazine	U&E in last 12m
	Methylphenidate	BP in last 6 months
	Methotrexate	FBC in last 3 months
	Mexiletine	LFT in last 6 months
	Modafinil	BP in last 6 months
	Mycophenolate	U&E in last 3 months
	Penicillamine	FBC in last 3 months
	Riluzole	FBC last 12 months

	Sirolimus Stiripentol Sulfasalazine Tacrolimus (excl topicals Warfarin	U+Es in last 12m LFT in last 6 months Children only LFT in last 3 months BP in last 12 months INR in last 3 months
Quarter Three – October, November & December	Depot Antipsychotics - Aripiprazole depot, Flupentixol decanoate depot, Fluphenazine decanoate depot, Haloperidol decanoate depot, Paliperidone depot, Risperidone long acting injection, , Zuclopenthixol depot Oral Antipsychotics 2nd generation -Amisulpride, Aripiprazole (oral), Olanzapine, Quetiapine, Risperidone (oral) Oral Antipsychotics 1st generation -Benperidol, Chlorpromazine, Flupentixol, Haloperidol, Pericyazine, Perphenazine, Pimozide, Promazine, Sulpiride, Trifluoperazine, Zuclopenthixol Azathioprine Carbamazepine DOACs Enoxaparin Entecavir Lamivudine Liothyronine Lithium Metyrapone Methotrexate Sacubitril valsartan Tinzaparin Warfarin	FBC last 12 months HBA1C in last 12 months HBA1C in last 12 months FBC in last 3 months U&E in last 12 months FBC in last 12 months FBC in last 12 months FBC in last 6 months LFT in last 6 months TSH in last 12 months Li Level in last 6m BP in last 3m FBC in last 3 months BP in last 6 months FBC in last 12 months INR in last 3 months

Quarter Four – January, February & March	Amiodarone	LFT in last 6 months
	Atomoxetine	BP in last 6 months
	Azathioprine	FBC in last 3 months
	Carbamazepine	U&E in last 12m
	Ciclosporin	BP in last 3 months
	Cinacalcet	PTH in last 3 months
	Demeclocycline	FBC in last 4 months
	Denosumab	U&E in last 6m
	Dexamfetamine	BP in last 6 months
	DOACs	FBC in last 12m
	Dronedarone	LFT in last 12m
	Guanfacine	BP in last 6 months
	Hydroxycarbamide	U&E in last 3m
	Leflunomide	U+Es in last 3m
	Levamisole	U+Es in last 3m
	Liothyronine	TSH in last 12m
	Lisdexamfetamine	BP in last 6 months
	Lithium	Lithium levels in last 6m
	Mercaptopurine	LFTs in last 3m
	Mesalazine	U&E in last 12m
	Methotrexate (oral)	FBC in last 3 months
	Methylphenidate	BP in last 6 months
	Mexiletine	LFT in last 6 months
	Modafinil	BP in last 6 months
	Mycophenolate	U+Es in last 3 months
	Penicillamine	FBC in last 3 months
	Riluzole	FBC last 12 months
	Sirolimus	U&E in last 12 months
	Stiripentol	LFT in last 6 months
	Sulfasalazine	Children only LFT in last 3 months
	Tacrolimus (exc topical)	BP in last 12 months
	Warfarin	INR in last 3 months

Results

Data will be suppled in the following format:

	Percentage Monitored							
Amber Audit	Target	%	PCN			CCG		
			%	Lowest	Highest	%	Lowest	Highest
% of pts DOAC issued Q2 HAD FBC last 15m	80%	44%	93%	44%	100%	95%	44%	100%
% of pts Issued Depot Antipsychotics last 84 days HAD FBC last 15m	80%	nil	100%	100%	100%	96%	0%	100%
% of pts Entecavir Issued last 84 days HAD FBC last 9m	80%	nil	56%	0%	100%	69%	0%	100%
% of pts issued Lamivudine last 84 days HAD LFT last 9m	80%	nil	100%	100%	100%	47%	0%	100%
% of pts issued Liothyronine last 84 days HAD TSH last 12m	80%	nil	100%	100%	100%	91%	0%	100%
% of pts Azathioprine HAD FBC last 6m	80%	100%	89%	50%	100%	92%	29%	100%
% of pts issued Carbamazepine (mood stabilisation) last 84 days HAD U&Es last 18m	80%	nil	85%	0%	100%	nil	0%	100%
% of pts Enoxaparin & Tinzaparin issued last 84 days had FBC last 15m	80%	0%	82%	0%	100%	80%	0%	100%
% of pts Metyrapone issued last 84 days HAD BP last 3m	80%	nil	nil	nil	nil	75%	0%	100%
% of pts Sacubitril Valsartan issued last 84 days HAD BP last 12m	80%	100%	97%	82%	100%	97%	50%	100%
% of pts issued oral antipsychotics 2nd generation last 84 days had HBA1C last 15m	80%	71%	85%	50%	99%	89%	33%	100%
% of pts issued oral antipsychotic 1st generation last 84 days had HBA1C last 15m	80%	0%	92%	0%	100%	86%	0%	100%
% of pts Lithium HAD lithium levels last 9m	80%	100%	95%	0%	100%	95%	0%	100%
% of pts Methotrexate HAD FBC last 6m	80%	nil	94%	73%	100%	96%	60%	100%
% of pts Warfarin HAD INR last 3m	80%	100%	100%	83%	100%	96%	73%	100%
% Total monitored	80%	63%	92%	63%	97%	94%	63%	99%

Target = 80%

Practice Resources

The searches used by the CCG to identify the number of patients with missing testing can be found:

SystmOne



NHS Leeds CCG/Medicines Commissioning /Amber Audit 202023

EMIS



In Leeds Central Reporting/Leeds Meds Data & Digital/20.21.22.23 Amber Audits

Please note: searches will update each time they are run.

Appendix 1

Antipsychotic Depot Injection prescription & administration payment
Quarter… 2022.23

Practice Name ……..……..

Completed by ……..…… Date …….

There is a 2 tier payment for depot antipsychotics:

Depots administered every 2 weeks will be paid at £66 per annum; those given less frequently than this will be paid at £40 per annum. The MOT will automatically run searches for depot antipsychotics prescribed each quarter and will pay practices at the default rate of £40. If you are happy with this there is no need to take any further action, however, if you have patients getting 2 weekly injections and wish to claim the higher rate please return details below.

Antipsychotic drug name	Number of patients getting 2 weekly injections

Please return this form to **leedsccg.prescribingteam@nhs.net** during the first 2 weeks of each quarter to claim for 2 weekly depot injects given during the previous quarter.